|
Jul 24
|
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
|
|
Jul 24
|
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
|
|
Jul 23
|
Ipsen announces changes to its Executive Committee
|
|
Jul 22
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025
|
|
Jul 17
|
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
|
|
Jul 16
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025
|
|
Jul 10
|
Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
Jun 20
|
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
|
|
Jun 17
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
|
|
Jun 13
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
|
|
Jun 12
|
Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
Feb 14
|
Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...
|
|
Feb 13
|
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
|
|
Oct 14
|
Ipsen receives its second Shingo Prize for operational excellence
|
|
Oct 9
|
Ipsen SA (IPSEF) (H1 2024) Earnings Call Highlights: Strong Sales Growth Amidst Challenges
|
|
Oct 9
|
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
Jul 26
|
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
|
|
Jul 25
|
Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
|
|
Jul 25
|
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
|
|
Jul 25
|
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
|